This Article Free Full Text (Free PDF) Free References Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Jacobson-Kram, D. Articles by Jacobs, A. C. Search for Related Content PubMed PubMed Citation Articles by Jacobson-Kram, D. Articles by Jacobs, A. C. Social Bookmarking                   What's this?

Use of Transgenic Mice in Carcinogenicity Hazard Assessment

Center for Drug Evaluation and Research, Food and Drug Administration, Rockville, Maryland 20850, USA, jacobsonkram{at}cder.fda.gov

Frank D. Sistare

Center for Drug Evaluation and Research, Food and Drug Administration, Rockville, Maryland 20850, USA

Abigail C. Jacobs

Center for Drug Evaluation and Research, Food and Drug Administration, Rockville, Maryland 20850, USA

Determining the carcinogenic potential of materials to which humans have significant exposure is an important, complex and imperfect exercise. Not only are the methods for such determinations protracted, expensive and utilize large numbers of animals, extrapolation of data from such studies to human risk is imprecise. Toxicologists have long recognized these shortcomings but the 2-year chronic rodent study has remained the gold standard. Recent developments in the field of molecular oncology and development of methods to insert or inactivate specific genes in animals have provided the tools with which to develop the next generation of carcinogenicity assays. With improved understanding of oncogene activation and tumor suppressor gene inactivation a number of animal models have been developed to dramatically reduce latency for chemically induced cancers. This has led to the development of shorter carcinogenicity assays. Also, because the spontaneous tumor frequencies in these animals are low during the in-life portion of the study, and studies are terminated well before the health complications of advanced aging are observed, it has been possible to reduce the group sizes and reduce animal usage. FDA's adoption of ICH S1B in 1997, (ICH, 1997) "Testing for the Carcinogenicity of Pharmaceuticals," opened the door for the use of such transgenic models in regulatory toxicology. This presentation reviews the current state of the science and its application to regulatory issues.

Key Words: Carcinogenicity testing • transgenic mice • p53 • Tg.AC • TgrasH2 • regulatory toxicology.

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this?